

PHARMACEUTICALS & BIOLOGICS

| | |
|--|----------|
| FANC: Potentiating Melphalan in Multiple Myeloma by Targeting the Fanconi Anemia/BRCA Resistance Pathway | 03B097 |
| VEGF/PDGF: Orally Bioavailable Small Molecule that Binds VEGF or PDGF for the Treatment of Cancer or Age-Related Macular Degeneration | 03B114 |
| RhoB: Gene Therapy with RhoB Variants to Suppress Cancer Growth | 04B102 |
| STAT3: Enhancing Immune Response to Tumor Cells | 04B112 |
| MRP1: Compounds for Treating Multidrug Resistance | 04MA001 |
| Raf/Mek/P-Erk: Inhibition of the Raf-1/Mek-1/Erk1/2 Pathway by the Beta-2-Adrenergic Receptor Agonist Pirbuterol | 05B072 |
| Src, Abl: Dasatinib on Drug-Eluting Stents for the Prevention and Treatment of Restenosis and Stenosis | 05B111N |
| Rb/Raf: Orally active disruptors of the Rb/Raf-1 binding interaction | 05B126 |
| Shp2: Indoline Scaffold Protein Tyrosine Phosphatase Inhibitors | 06A038 |
| BCR-ABL: Vorinostat co-treatment enhances dasatanib efficacy in CML | 06B078N |
| Rho Kinase: Inhibitors as Novel Anti-Cancer Agents | 06B134 |
| Glut-1: Glucose Transporter Inhibitor Antibodies | 07B083 |
| SHIP: Inhibitors for Treating Graft vs. Host Disease and Transplant Rejection | 08MB010 |
| Topoisomerase II: Inhibitors of Nuclear Export of Topoisomerase II Alpha | 08MB014 |
| Aurora: Aurora A Kinase Inhibitors | 09MA037 |
| pH: Inhibition of Metastasis with Systemic Non-volatile Buffers | 09MB048 |
| Mcl-1: Asymmetrical Marinopyrroles as Anti-Cancer Agents | 10MA018N |
| LPAAT: Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer | 10MA019N |
| FT/GGT: Farnesyltransferase/ Geranylgeranyltransferase Dual Inhibitor | 10MB048 |
| Topoisomerase II: Inhibitor Enhancer in Multiple Myeloma | 10MB078 |
| Proteasome: Non-covalent and Reversible Proteasome Inhibitors with an Oxadiazole-isopropylamide Core | 10MB083 |
| SHP2: Novel Small Molecule Oxindole Tyrosine Phosphatase Inhibitor | 12MA024N |
| HDAC6: Novel Small Molecule Histone Deacetylase 6 Inhibitor with a Substituted Aryl Urea Cap Group | 12MA030 |
| Mcl-1/Bcl-xL: Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents | 12MA035N |
| IRE-1: Novel Small Molecule Inhibitors of IRE-1 for Treatment of B-cell Cancer | 12MB089 |
| STAT3: STAT3 Dimerization Inhibitors | 12MB098 |
| Anti-infectives: Symmetrical Synthetic Marinopyrroles as anti-MRSA Therapeutics | 12MB110 |
| BRD4 JAK2: Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics | 14MB069 |
| WEE1: Small molecule WEE1 inhibitor to treat cancer that inhibits WEE1 phosphorylation of H2B but not Cdc2 | 14MB092N |
| Ras: Inhibitors of the Binding of GTP to Oncogenic Mutant K-Ras | 15MA011 |
| Ras/Raf: Stapled Peptides Designed to Inhibit the K-Ras/Raf Interaction | 15MA012 |
| Aurora/JAK2: Dual Kinase Inhibitor targeting JAK2 and Aurora Kinase A for GVHD Prophylaxis | 16MA005N |
| β-catenin/BCL-9: Small molecule inhibitors of the interaction of β -catenin and BCL-9 | 17MA014 |
| β-catenin/TCF: Small molecule inhibitors of the interaction of β -catenin and T-cell Factor | 17MB040N |

FOR ADDITIONAL INFORMATION CONTACT

Haskell Adler PhD MBA CLP
 Sr. Licensing Manager, Registered Patent Agent
haskell.adler@moffitt.org
 (813) 745-6596

Jarett Rieger Esq. MBA
 Sr. Director, Innovation Office
jarett.rieger@moffitt.org
 (813) 745-6828

DIAGNOSTICS, IMMUNOTHERAPIES,
 DEVICES, TOOLS, SOFTWARE

6.6.2018



IMMUNOTHERAPIES

| | |
|--|----------|
| Vaccine Adjuvant: Flagellin-Based Adjuvant for Tumor Cell Vaccines that binds TLR5 | 04A028 |
| Antibodies: MARCO for Enhanced Dendritic Cell Vaccine Efficacy | 07MB004 |
| Vaccine: Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination | 11MA013 |
| TAG72-CD3: Bispecific Antibody for Targeted Cancer Immunotherapy | 14MB072 |
| Cancer Vaccine: Full-Length Variant Survivin Vaccine Potentiates Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma | 14MB098 |
| TLR9: CAR-T cell constructs (chimeric antigen receptors) that Recognize TLR9 | 16MA025 |
| DOR: Delta opioid receptor ligand and anti-PD1 checkpoint inhibitor conjugates for immunotherapy of lung cancer | 16MA029N |
| AaPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain for Producing CAR-Ts | 16MB049 |
| AaPC: Artificial Antigen-Presenting Cells for Expanding TILs/MILs in Cancer Immunotherapy | 16MB050 |
| TAG72: CAR-T cell constructs (chimeric antigen receptors) that Recognize TAG72 | 16MB057 |
| IL-13Rα2: CAR-T cell constructs (chimeric antigen receptors) that Recognize IL-13R α 2 | 16MB069 |
| CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy | 17MA007 |
| TILs: Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors | 17MA012 |
| CLEC12A: CAR-T cell constructs (chimeric antigen receptors) that Recognize CLEC12A to Treat AML | 17MA041 |
| CD99: CAR-T cell constructs (chimeric antigen receptors) that Recognize CD99 to Treat AML | 17MA042 |
| TILs: Method to Increase TILs by Administering Fucose to a Patient | 17MB048 |
| MIC & RAET1/ULBP: CAR-T CELL constructs that use the NKG2D protein to bind MIC and RAET1/ULBP proteins to treat AML | 18MA023N |
| TILs: A New Digest Method for the Preparation of TILs | 18MA026N |
| CAR-T: Improved CAR-T 41BB and CD28 Costimulatory Domains | 18MA027N |

DIAGNOSTICS

| | |
|--|----------|
| Protein Diagnostic: Characterization of Quantum Dots for Ovarian Cancer Detection | 04A064 |
| Protein Signature: Discriminating Common Adenocarcinomas | 05A014 |
| Genetic Signature: Metastatic Melanoma Stage Identification | 06B073 |
| Plasma Protein Biomarker: Diagnosis of Ovarian Cancer | 06B098 |
| Protein Biomarker: Predicting Response to Immunosuppression in MDS | 07A056 |
| Genetic Signature: Predicting Tumor Aggressiveness | 07B108 |
| Protein Biomarker: Diagnostic Marker for AML and MPD | 07B113 |
| Genetic Signature: Malignancy Risk Signature to Predict High-Risk Normal Breast Tissues | 08A016 |
| Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence | 08MA005 |
| Genetic Signature: Lymph Node Formation for Prognosis of Colorectal Cancer | 09MA014 |
| Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP) | 10MA009 |
| Genetic Signature: Predicting High Grade Glioma Outcomes Using Senescence Associated Genes | 10MA013 |
| Molecular Imaging Probe: Non-invasive Detection of Breast Cancer in Lymph Nodes | 10MA024 |
| Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery | 10MB069N |
| Genetic Signature: CREB Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking | 11MA006 |
| Protein Diagnostic: Protein-Protein Interaction (PPI) Biomarkers | 11MA014 |
| Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images | 11MA022 |

FOR ADDITIONAL INFORMATION CONTACT

PHARMACEUTICALS & BIOLOGICS

Haskell Adler PhD MBA CLP
 Sr. Licensing Manager, Registered Patent Agent
haskell.adler@moffitt.org
 (813) 745-6596

Jarett Rieger Esq. MBA
 Sr. Director, Innovation Office
jarett.rieger@moffitt.org
 (813) 745-6828

DIAGNOSTICS, DEVICES TOOLS, SOFTWARE



DIAGNOSTICS (cont.)

| | |
|--|----------|
| Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma | 11MA026N |
| Genetic Signature: Method of Detecting MDS Using hTERT Activity | 11MB061N |
| Molecular Imaging Probe: Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes | 11MB064 |
| Genetic Signature: Predicting Response to Cancer Immunotherapy | 11MB069 |
| Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia | 11MB072N |
| Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins | 11MB087N |
| Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC | 12MA023N |
| Genetic Signature: O-glycan Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking | 12MA034 |
| Genetic Signature: Determining Prostate Cancer Recurrence Using Polymorphisms In Angiogenesis Genes | 12MA045 |
| Molecular Imaging Probe: Probes for Lung Cancer Intraoperative Guidance | 12MA050N |
| Genetic Signature: E2F/Rb pathway signature to predict patient benefit from adjuvant chemo in NSCLC | 12MA069 |
| Molecular Imaging Probe: A Novel ¹⁸ F Scaffold for Preparing Targeted PET Imaging Probes | 12MB104 |
| Protein Diagnostic: Phosphorylated STAT3 Protein as a Biomarker of Graft Versus Host Disease | 13MA002 |
| Multiplex Diagnostic: RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma | 13MA009 |
| Genetic Signature: Predicting Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer | 13MA036 |
| Imaging: Decision Support Tool for Oncology Treatment that Analyzes Radiological Images | 13MB047 |
| Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma | 13MB048N |
| Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis | 13MB054 |
| Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma | 13MB055 |
| Molecular Imaging: Novel PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging | 13MB056N |
| miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs) | 13MB078 |
| miRNA Diagnostic: Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma | 13MB080 |
| Protein Biomarker: Expression of WEE1 and PAXIP1 Can Select Patients who Respond to WEE1 Inhibitor Therapy | 14MA001 |
| Genetic Signature: Predicting Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery | 14MA008 |
| Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy | 14MA052N |
| Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients | 15MA015 |
| Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation May Be Specific Biomarkers for MDS | 15MA021N |
| Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration | 15MA031N |
| Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes | 15MB042N |

FOR ADDITIONAL INFORMATION CONTACT

DIAGNOSTICS, IMMUNOTHERAPIES PHARMACEUTICALS & BIOLOGICS

Haskell Adler PhD MBA CLP
 Sr. Licensing Manager, Registered Patent Agent
haskell.adler@moffitt.org
 (813) 745-6596

Jarett Rieger Esq. MBA
 Sr. Director, Innovation Office
jarett.rieger@moffitt.org
 (813) 745-6828

DIAGNOSTICS DEVICES, TOOLS SOFTWARE



DIAGNOSTICS (cont.)

| | |
|--|---------|
| Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression | 15MB065 |
| Genetic Signature: Diagnostic to Distinguish Lung Carcinoma from Metastatic Head & Neck Carcinoma | 16MB040 |
| Protein Biomarker: Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict whether Cystectomy (bladder removal) would have a Better Outcome than Bladder-sparing Therapy with Chemoradiation | 16MB041 |
| Protein Biomarker: Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients treated with Lenalidomide | 16MB042 |
| Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent | 16MB044 |
| miRNA Diagnostic: Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma | 16MB066 |
| miRNA Diagnostic: miRNA Signature combined with Radiological Features for Non-invasive Early Detection of Malignancy in IPMN | 17MA001 |
| Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment in Cancer | 17MA025 |

DEVICES, TOOLS & SOFTWARE

| | |
|--|----------|
| Med Device: Objective Imaging Reference Standards | 07A049 |
| Med Device: Ventana Inline Dispenser Float Mechanism | 09MB053 |
| Med Device: Handheld Radioisotope Identification Device (RIID) | 10MB054 |
| Med Device: Muscle Stapler | 10MB065N |
| Med Device: Pump-assisted High Flow Rate Isolated Limb Infusion for Regional Cancer Treatment | 11MA017N |
| Med Device: Minimally Invasive Spinal Fusion Using a Transdiscal Screw System | 11MA021 |
| Med Device: Improved Endotracheal Tube to Prevent Intubation Related Complications Related to Airway Edema (Swelling) | 11MA052 |
| Med Device: Vascular Stent for Anastomosis | 12MA054N |
| Med Device: Arterial Line Catheter Modification | 12MA067 |
| Med Device: Improved Enteral Feeding Tube and Retention Disc to Reduce Dislodgement, Infection and Complications | 13MA001 |
| Med Device: Improved Orogastric Tube Guide | 13MA030 |
| Med Device: Expandable Intervertebral Cage for Spinal Fusion | 14MB067N |
| Med Device: Improved Pigtail Drainage Catheter for Percutaneous Fluid Aspiration | 15MA034 |
| Med Device: Safety Catheter with Needle and Blood Exposure Prevention Systems | 15MB064 |
| Med Device: Novel Endotracheal Tube Intubating Stylet | 16MA021 |
| Med Device: Anesthesia Intra-oral Monitoring System (AIMS) (Replacement for the Nasal Cannula) | 16MB046 |
| Research Tool: Novel Electroporation Buffer Formulation for Enhanced Efficiency and Viability | 05B141 |
| Software: Method for Improved Detection of Lung Function and Management of Lung Cancer Radio Therapy | 10MA037N |
| Software: Method for Improving the Accuracy of Charged Particle Beam Radiotherapy | 12MB072 |
| Software: Automated Technique for Generating BIRADS Scores from Mammograms | 13MA025 |
| Software: BMT Research Analysis Information Network (BRAIN) to Facilitate the Automation of AGNIS/CIBMTR Forms | 13MA053 |
| Software: Decision Support Tool for Oncology Treatment using Mathematical Simulations | 13MB073 |
| Software: A Quantitative Framework to Identify Radiation Targets for Cancer Treatment that Synergize with Immunotherapy (Abscopal Effect) | 14MA022 |
| Software: Negative Information Storage Model for Genomic Data | 15MA033 |
| Copyright: Energize mBC: Web-based Program to Treat Fatigue in Metastatic Breast Cancer Patients | 17MC003 |

PHARMACEUTICALS & BIOLOGICS, DIANOSTICS IMMUNOTHERAPIES

Haskell Adler PhD MBA CLP
 Sr. Licensing Manager, Registered Patent Agent
haskell.adler@moffitt.org
 (813) 745-6596

Jarett Rieger Esq. MBA
 Sr. Director, Innovation Office
jarett.rieger@moffitt.org
 (813) 745-6828

